Literature DB >> 11583754

Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.

F Ratjen, G Döring, W H Nikolaizik.   

Abstract

Early antibiotic treatment of airway colonisation with Pseudomonas aeruginosa can delay onset of chronic lung infection in patients with cystic fibrosis. Whether the pathogen is eradicated by this treatment is unclear. We successfully eradicated the organism in 14 of 15 patients with cystic fibrosis who had been colonised by P aeruginosa. Patients inhaled 80 mg tobramycin twice daily for 12 months. Eradication was confirmed by sequential respiratory cultures and serum antibody titres that were negative for P aeruginosa. Our antibiotic therapy regimen maintained pulmonary function at high levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583754     DOI: 10.1016/S0140-6736(01)06124-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  41 in total

1.  Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.

Authors:  Christiane Beckmann; Mitchell Brittnacher; Robert Ernst; Nicole Mayer-Hamblett; Samuel I Miller; Jane L Burns
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 2.  Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Authors:  Souha S Kanj; Zeina A Kanafani
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

3.  Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections.

Authors:  María D Maciá; David Blanquer; Bernat Togores; Jaume Sauleda; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.

Authors:  María I Morosini; María García-Castillo; Elena Loza; María Pérez-Vázquez; Fernando Baquero; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

Review 5.  What's new in cystic fibrosis? From treating symptoms to correction of the basic defect.

Authors:  Marijke Proesmans; François Vermeulen; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2008-04-04       Impact factor: 3.183

Review 6.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 7.  Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature.

Authors:  Federico Marchetti; Luisella Giglio; Manila Candusso; Dino Faraguna; Baroukh M Assael
Journal:  Eur J Clin Pharmacol       Date:  2004-03-05       Impact factor: 2.953

Review 8.  Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.

Authors:  Matthew Hurley; Alan Smyth
Journal:  Ther Adv Respir Dis       Date:  2012-09-11       Impact factor: 4.031

9.  Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis.

Authors:  Philip M Farrell; Jannette Collins; Lynn S Broderick; Michael J Rock; Zhanhai Li; Michael R Kosorok; Anita Laxova; William M Gershan; Alan S Brody
Journal:  Radiology       Date:  2009-08       Impact factor: 11.105

10.  Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  Samuel M Moskowitz; Jessica M Foster; Julia Emerson; Jane L Burns
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.